These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31390883)

  • 1. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors.
    Kegulian NC; Ramms B; Horton S; Trenchevska O; Nedelkov D; Graham MJ; Lee RG; Esko JD; Yassine HN; Gordts PLSM
    Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2145-2156. PubMed ID: 31390883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
    Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD
    J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease.
    Olivieri O; Chiariello C; Martinelli N; Castagna A; Speziali G; Girelli D; Pizzolo F; Bassi A; Cecconi D; Robotti E; Manfredi M; Conte E; Marengo E
    Clin Chem Lab Med; 2018 Aug; 56(9):1542-1550. PubMed ID: 29652662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.
    Koska J; Yassine H; Trenchevska O; Sinari S; Schwenke DC; Yen FT; Billheimer D; Nelson RW; Nedelkov D; Reaven PD
    J Lipid Res; 2016 May; 57(5):894-905. PubMed ID: 26945091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
    Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
    J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice.
    Foley EM; Gordts PLSM; Stanford KI; Gonzales JC; Lawrence R; Stoddard N; Esko JD
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2065-74. PubMed ID: 23846497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides.
    Yassine HN; Trenchevska O; Ramrakhiani A; Parekh A; Koska J; Walker RW; Billheimer D; Reaven PD; Yen FT; Nelson RW; Goran MI; Nedelkov D
    PLoS One; 2015; 10(12):e0144138. PubMed ID: 26633899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions.
    Mendoza S; Trenchevska O; King SM; Nelson RW; Nedelkov D; Krauss RM; Yassine HN
    J Clin Lipidol; 2017; 11(1):224-233.e2. PubMed ID: 28391889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.
    Mann CJ; Troussard AA; Yen FT; Hannouche N; Najib J; Fruchart JC; Lotteau V; André P; Bihain BE
    J Biol Chem; 1997 Dec; 272(50):31348-54. PubMed ID: 9395464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
    Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
    J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
    [No Abstract]   [Full Text] [Related]  

  • 11. Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects.
    Rodríguez M; Rehues P; Iranzo V; Mora J; Balsells C; Guardiola M; Ribalta J
    J Proteomics; 2022 Jan; 251():104398. PubMed ID: 34688878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
    Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
    Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adaptor protein PID1 regulates receptor-dependent endocytosis of postprandial triglyceride-rich lipoproteins.
    Fischer AW; Albers K; Krott LM; Hoffzimmer B; Heine M; Schmale H; Scheja L; Gordts PLSM; Heeren J
    Mol Metab; 2018 Oct; 16():88-99. PubMed ID: 30100244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
    Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
    J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
    Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
    Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of severe caloric restriction on the degree of sialylation of apoprotein C-III in obese women.
    Bosello O; Cominacini L; Zocca I; Garbin U; Ferrari F; Davoli A
    Ann Nutr Metab; 1985; 29(1):33-9. PubMed ID: 3977292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.
    Fredenrich A; Giroux LM; Tremblay M; Krimbou L; Davignon J; Cohn JS
    J Lipid Res; 1997 Jul; 38(7):1421-32. PubMed ID: 9254067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
    Chan DC; Watts GF
    Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
    Schmitz J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.